MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?

Not Applicable

Completed

• Conditions: Neoplasms

• Registration Number: NCT03299855
• Lead Sponsor: Centre Francois Baclesse

Brief Summary

This study concerns elderly patients with cancer with onco-geriatric assessment.

This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the MoCA and the MMS tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. The results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-09-26
• Study First Submitted QC: 2017-10-02
• Study First Posted: 2017-10-03
• Study Start: 2017-10-13
• Status Verified: 2023-09
• Primary Completion: 2023-10-13
• Study Completion: 2023-10-13
• Last Update Submitted: 2023-10-17
• Last Update Posted: 2023-10-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

• Patient aged over 70 years
• Patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). Surgery and radiotherapy are allowed before entry into the study.
• Patient candidate for oncogeriatric assessment
• Patient agree to participate in the study
• Using the French language

Exclusion Criteria

• Primary central nervous system or cerebral metastasis
• Evolutionary psychiatric pathology known (e.g. schizophrenia)
• Severe Visual and / or Auditory Impairment
• Patients unable to respond to cognitive tests
• Patient (s) deprived of liberty, under guardianship or curatorship
• Refusal of participation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Evaluate the sensitivity of MoCA test	Up 2 months after inclusion, before initiation of treatment	MoCA is considered clinically relevant if its sensitivity to identify patients with cognitive impairment is at least 75%

Trial Locations

Locations (6)

Centre François Baclesse; 🇫🇷 Caen, France

CHU; 🇫🇷 Caen, France

Centre Henri Becquerel; 🇫🇷 Rouen, France

CH; 🇫🇷 Cherbourg, France

Ch Compiegne; 🇫🇷 Compiègne, France

Centre Hospitalier; 🇫🇷 Saint-Lô, France